Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Buy-and-Bill

COVID-19

Case-Based Roundtable

Chronic Hand Eczema

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Editorial Advisory Board

Partners

Subscribe

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Articles

Jackson discusses EVO756, a promising MRGPRX2 antagonist targeting mast cells to treat chronic inflammatory diseases like spontaneous urticaria.

Exploring EVO756 in Chronic Inflammatory Disease Treatment: Q&A with Evommune's Mark Jackson, MD

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and is now finishing her Masters in Digital Media through Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family.

Catch up on exclusive interviews with Christopher Bunick, MD, PhD; Raj Chovatiya, MD, PhD; and Alexander Egeberg, MD, PhD, from quarter 4 dermatologic conferences.

2024 Insights: Unmet Needs, Therapeutic Innovations, and Pivotal Findings in Chronic Hand Eczema

Karan Lal, DO; Lisa Swanson, MD; James Song, MD; Andrew Alexis, MD, MPH; and Lawrence Eichenfield, MD, discussed the complexities of vitiligo care and the potential of innovative topical therapies.

Treatment Insights and Evolving Care Options in Vitiligo 

Marie Bosslett is the assistant editor of 

 and joined the MJH Life Sciences team in October 2024. She attended Loyola University Maryland in Baltimore and earned a Bachelor of Arts in Communication with minors in marketing and writing. When she’s not writing, Marie enjoys going to concerts, reading on the beach, and spending time with friends and family.

Take a look back at this year's newly FDA-approved dermatology devices and drugs.

2024 Drug & Device Approvals in Review

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

View

Managing Vitiligo: Case Studies and Community Treatment Perspectives

Managing Long-Standing Vitiligo With Facial Involvement: Case-Based Insights Into OTC Solutions, Repigmentation, and Relapse Prevention

Videos

Pearl E. Grimes, MD,discusses managing long-standing vitiligo through various strategies, including combination therapies for stabilization and repigmentation, OTC solutions for facial involvement, and the evolving role of FDA-approved topical ruxolitinib in redefining treatment paradigms.

Pearl E. Grimes, MD, provides case-based insights on managing long-standing vitiligo with extensive depigmentation and atopic comorbidities, focusing on treatment history, comorbid conditions, and the impact on quality of life.

Case-Based Insights: Managing Long-Standing Vitiligo With Extensive Depigmentation and Atopic Comorbidities

Pearl E. Grimes, MD, discusses strategies for optimizing vitiligo stabilization and repigmentation through combination therapies, emphasizing long-term maintenance, treatment modalities, and the use of topical agents like tacrolimus and ruxolitinib cream.




Optimizing Vitiligo Stabilization and Repigmentation With Combination Therapies

Pearl E. Grimes, MD, explores managing long-standing vitiligo with facial involvement, focusing on over-the-counter solutions, repigmentation strategies, and relapse prevention techniques.



Pearl E. Grimes, MD, discusses the evolving treatment paradigm for vitiligo, highlighting the role of FDA-approved topical ruxolitinib and its impact on management strategies.


Redefining Vitiligo Management: FDA-Approved Topical Ruxolitinib and the Evolving Treatment Paradigm

Case Based Peer Perspectives

Managing Long-Standing Vitiligo With Facial Involvement: Case-Based Insights Into OTC Solutions, Repigmentation, and Relapse Prevention

EP: 1.Case-Based Insights: Managing Long-Standing Vitiligo With Extensive Depigmentation and Atopic Comorbidities

EP: 2.Optimizing Vitiligo Stabilization and Repigmentation With Combination Therapies

EP: 3.Managing Long-Standing Vitiligo With Facial Involvement: Case-Based Insights Into OTC Solutions, Repigmentation, and Relapse Prevention

EP: 4.Redefining Vitiligo Management: FDA-Approved Topical Ruxolitinib and the Evolving Treatment Paradigm